Tempo Therapeutics, Inc.
PrivateLast Round
Series B
Aug 27, 2026
Total Funding Raised
$14.3M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Tempo Therapeutics, Inc. operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was an Accelerator round in June 2025.
Tempo Therapeutics, Inc. is a biotechnology company developing synthetic biomaterials for use in a variety of surgical reconstruction and therapeutic regenerative applications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Advanced Materials, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tempo Therapeutics, Inc. Comparables
Compare Tempo Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BioMimir Inc. | 79% | |
| inSoma Bio | 79% | |
| EpiBone | 78% |
For institutional investors. Book with your work email.
Tempo Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 27, 2026 | ||||
| Accelerator | Jun 5, 2025 | ||||
| Series A | Mar 19, 2024 | ||||
| Grant | Nov 17, 2020 | ||||
| Early Funding | May 21, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Tempo Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Mesa Verde Venture Partners | Series B |
| MedTech Innovator | Accelerator |
| NIH RADx | Grant |
| YK Bioventures | Series A, Series B |
| AJAX Capital Partners | Series A |
| Gideon Strategic Partners | Series B |
| National Institutes of Health (NIH) | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 27, 2026
$14M raised in early funding.
- Jun 20, 2026
Monthly visitors increased 230% MoM, reaching 5.5K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingSep 23, 2026
On Sep 23rd '26, Tempo Therapeutics receives a $2.25M Small Business Innovation Research grant from the National Cancer Institute, part of the NIH, to support a randomized clinical study of its MAP Wound Matrix in California.
- receives_awardSep 23, 2026
Tempo Therapeutics received a Small Business Innovation Research (SBIR) award from the National Cancer Institute, part of the National Institutes of Health, to support a randomized clinical study of its MAP Wound Matrix in California on Sep 23rd '26.
For institutional investors. Book with your work email.
Tempo Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Tempo Therapeutics, Inc.'s valuation, stock price, and market status.
Is Tempo Therapeutics, Inc. a public or private company?
Tempo Therapeutics, Inc. is a private company.
What is the current stock price of Tempo Therapeutics, Inc.?
Tempo Therapeutics, Inc. is a private company, so its shares have no public market price. Caplight tracks Tempo Therapeutics, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Tempo Therapeutics, Inc. worth (valuation)?
Valuation information for Tempo Therapeutics, Inc. is not publicly available.
Can I buy Tempo Therapeutics, Inc. stock?
Tempo Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Tempo Therapeutics, Inc.'s last funding round?
Tempo Therapeutics, Inc.'s most recent funding round was Series B on August 27, 2026.
Who are the main investors in Tempo Therapeutics, Inc.?
Key investors in Tempo Therapeutics, Inc. include Johnson & Johnson Innovation – JJDC, Johnson & Johnson Innovation - JJDC, Inc..
Will Tempo Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for Tempo Therapeutics, Inc..
How can I track Tempo Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Tempo Therapeutics, Inc.'s shares on secondary markets.